
Please try another search
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Paul Andrew Fry | 59 | 2020 | Independent Non-Executive Director |
Alan Ho | - | 2024 | Member of Scientific Advisory Board |
William D. Tap | - | 2024 | Chairman of Scientific Advisory Board |
Christina Marie Coughlin | 55 | 2022 | CEO & Executive Director |
Anthony F. Yu | - | 2024 | Member of Scientific Advisory Board |
Lee D. Cranmer | - | 2024 | Member of Scientific Advisory Board |
Shaun Edward Chilton | 58 | 2023 | Independent Non-Executive Chairman |
Andrea Napolitano | - | 2024 | Member of Scientific Advisory Board |
Mark Alan Goldberg | 71 | 2021 | Independent Non-Executive Director |
Robin Jones | - | 2024 | Member of Scientific Advisory Board |
David John Bryant | 58 | 2025 | Independent Non-Executive Director |
Richard Ian Hughes | 57 | 2025 | Independent Non-Executive Director |
Robert Metcalf | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review